Clinical Trials
Numerous clinical trials evaluate interventions across diverse conditions, including central nervous system malignancies like glioblastoma and astrocytoma, Alzheimer's disease psychosis, and solid tumors such as ovarian carcinoma. Spanning Phase 1 through Phase 4 alongside combined Phase 2/3 studies, these protocols reflect early safety and late-stage efficacy assessments sponsored by pharmaceutical entities like Pfizer and ACADIA Pharmaceuticals as well as government bodies like the National Cancer Institute. Current recruitment statuses across these investigations range from active recruitment and completed evaluations to terminated trials.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03391778 | ENROLLING_BY_INVITATION | Neoplasms |
USWM CT, LLC |
2018-04-09 | PHASE1 |
| NCT04511039 | RECRUITING | Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 |
Roswell Park Cancer Institute |
2021-06-08 | PHASE1 |
| NCT07088588 | NOT_YET_RECRUITING | Advanced Solid Cancer; Metastatic Solid Tumor; Ovarian Cancer; Breast Cancer; BRCA Mutation; HRR Deficiency |
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd |
2025-07-31 | PHASE1 |
| NCT06415422 | NOT_YET_RECRUITING | Hematoma, Subdural |
University Hospital, Brest |
2026-07-01 | |
| NCT06785077 | RECRUITING | Leukemia, Myeloid, Acute; Myeloid Dysplasia; Ovarian Epithelial Cancer |
European Institute of Oncology |
2020-10-02 | |
| NCT06502691 | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma |
University of Washington |
2026-02-26 | PHASE1; PHASE2 |
| NCT06525298 | RECRUITING | Advanced Solid Tumor; Homologous Recombination Deficiency; HRR Deficiency |
Eisbach Bio GmbH |
2024-09-09 | PHASE1; PHASE2 |
| NCT06204991 | RECRUITING | Melanoma Stage III; Melanoma Stage IV; Melanoma |
Inge Marie Svane |
2025-04-01 | PHASE1 |
| NCT03334500 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Abramson Cancer Center at Penn Medicine |
2017-07-14 | EARLY_PHASE1 |
| NCT05686798 | RECRUITING | Malignant Glioma of Brain; Astrocytoma; Malignant Astrocytoma; Brain Tumor; Glioma; Brain Cancer; Glioblastoma; Glioblastoma Multiforme; GBM |
Henry Ford Health System |
2022-11-29 | PHASE1 |
| NCT04044859 | ACTIVE_NOT_RECRUITING | Endometrial Cancer; Esophageal Cancer; Esophagogastric Junction (EGJ); Gastric (Stomach) Cancer; Head and Neck Cancer; Melanoma; Ovarian Cancer; Non-small Cell Lung (NSCLC); Urothelial Cancer |
USWM CT, LLC |
2019-08-20 | PHASE1 |
| NCT03728049 | RECRUITING | Aortic Valve Stenosis; Aortic Valve Insufficiency |
University Hospital, Lille |
2019-12-18 | |
| NCT05601752 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
USWM CT, LLC |
2023-06-26 | PHASE2 |
| NCT07074808 | COMPLETED | Chest Pain; Emergencies |
Singapore General Hospital |
2022-11-11 | PHASE4 |
| NCT02469129 | UNKNOWN | Cancer |
Washington University School of Medicine |
2015-03 | EARLY_PHASE1 |
| NCT05494580 | COMPLETED | Ovarian Cancer; Ovarian Carcinoma; Platinum-resistant Ovarian Cancer; Fallopian Tube Carcinosarcoma; Primary Peritoneal Cancer |
Sun Yat-sen University |
2022-09-22 | PHASE1; PHASE2 |
| NCT05002868 | COMPLETED | Solid Tumor; Extensive-stage Small-cell Lung Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer; Platinum-sensitive Ovarian Cancer; Platinum-Sensitive Fallopian Tube Carcinoma; Platinum-Sensitive Peritoneal Cancer |
Rhizen Pharmaceuticals SA |
2021-10-05 | PHASE1 |
| NCT06194799 | Not yet recruiting | Alzheimer''s Disease Psychosis |
ACADIA Pharmaceuticals Inc. |
2024-04 | Phase 3 |
| NCT06213155 | Recruiting | Trigeminal Neuralgia |
St. Olavs Hospital |
2024-01 | Not Applicable |
| NCT06169319 | Recruiting | Plantar Fasciitis |
Endo Pharmaceuticals |
2023-12-12 | Phase 2 |
| NCT06159673 | Recruiting | Alzheimer''s Disease Psychosis |
ACADIA Pharmaceuticals Inc. |
2023-11-14 | Phase 2|Phase 3 |
| NCT06100510 | Not yet recruiting | Effect of Drug |
Hematology Oncology Associates of Central New York |
2023-11 | Phase 4 |
| NCT04752358 | TERMINATED | Esophageal Cancer; Esophagogastric Junction Cancer |
Adaptimmune |
2021-09-15 | PHASE2 |
| NCT04321317 | COMPLETED | Anorexia Nervosa |
Hospices Civils de Lyon |
2021-04-19 | |
| NCT04739046 | UNKNOWN | Pancreas Cancer |
Seoul National University Bundang Hospital |
2021-02-01 | PHASE2 |
| NCT03330405 | TERMINATED | Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors |
Pfizer |
2017-10-19 | PHASE1; PHASE2 |
| NCT03642132 | TERMINATED | Ovarian Cancer |
Pfizer |
2018-07-19 | PHASE3 |
| NCT04408898 | WITHDRAWN | Head and Neck Cancer |
Adaptimmune |
2020-07-02 | PHASE2 |
| NCT04044768 | ACTIVE_NOT_RECRUITING | Synovial Sarcoma; Myxoid Liposarcoma |
USWM CT, LLC |
2019-08-13 | PHASE2 |
| NCT03343054 | COMPLETED | Neoplasms; Breast Neoplasms |
Pfizer |
2017-11-30 | PHASE1 |
| NCT03016338 | ACTIVE_NOT_RECRUITING | Endometrial Cancer |
University Health Network, Toronto |
2017-11-06 | PHASE2 |
| NCT02878785 | COMPLETED | Acute Myeloid Leukemia |
University of Maryland, Baltimore |
2016-08 | PHASE1; PHASE2 |
| NCT03509636 | COMPLETED | Ovarian Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2018-04-04 | PHASE1 |
| NCT01012817 | ACTIVE_NOT_RECRUITING | Metastatic Malignant Solid Neoplasm; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable Solid Neoplasm |
National Cancer Institute (NCI) |
2009-11-03 | PHASE1; PHASE2 |
| NCT02686008 | WITHDRAWN | Squamous Cell Carcinoma of the Head and Neck |
Yale University |
2018-01 | PHASE1 |
| NCT03029871 | WITHDRAWN | Non-small Cell Lung Cancer Stage I |
Benjamin Movsas, M.D. |
2017-01-13 | PHASE1 |
| NCT02116777 | COMPLETED | Adult Solid Neoplasm; Childhood Solid Neoplasm; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Malignant Solid Neoplasm; Refractory Central Nervous System Neoplasm |
National Cancer Institute (NCI) |
2014-05-16 | PHASE1; PHASE2 |
| NCT02782325 | TERMINATED | Pouchitis |
University of North Carolina, Chapel Hill |
2017-06-01 | PHASE1; PHASE2 |
| NCT02894944 | COMPLETED | Pancreatic Cancer |
Seoul National University Hospital |
2016-08 | PHASE1 |
| NCT03111420 | COMPLETED | Risk Factor, Cardiovascular; Platelet Dysfunction Due to Drugs |
Aggredyne, Inc. |
2017-01-09 | |
| NCT01514201 | COMPLETED | Anaplastic Astrocytoma; Brain Stem Glioma; Childhood Mixed Glioma; Fibrillary Astrocytoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Fibrillary Astrocytoma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliosarcoma |
National Cancer Institute (NCI) |
2012-02-01 | PHASE1; PHASE2 |
| NCT01540565 | COMPLETED | BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ovarian Epithelial Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2012-04-09 | PHASE2 |
| NCT03027934 | WITHDRAWN | Diabetes Mellitus |
CirQuest Labs, LLC |
2017-08-28 | PHASE4 |
| NCT02627521 | UNKNOWN | Coronary Artery Disease |
Unity Health Toronto |
2015-07 | PHASE4 |
| NCT02500901 | TERMINATED | Metastatic Prostate Cancer |
Paul Mathew, MD |
2016-03 | PHASE1 |
| NCT02326844 | TERMINATED | Ovarian Cancer |
National Cancer Institute (NCI) |
2015-03-02 | PHASE2 |
| NCT01618136 | COMPLETED | Malignant Solid Tumour; Ovarian Cancer; Triple Negative Breast Cancer; Advanced Melanoma; B-cell Malignancy, Low-grade |
Eisai Limited |
2012-01 | PHASE1; PHASE2 |
| NCT02516267 | COMPLETED | Bleeding |
University of Sao Paulo General Hospital |
2015-07 | |
| NCT00687765 | COMPLETED | Glioblastoma |
Sanofi |
2008-07 | PHASE1; PHASE2 |
| NCT01352702 | TERMINATED | Coronary Heart Disease; Atrial Fibrillation; Acute Coronary Syndrome; Atherosclerosis |
Deutsches Herzzentrum Muenchen |
2011-05 | PHASE4 |
| NCT01009190 | COMPLETED | Advanced Solid Tumors |
pharmaand GmbH |
2010-02 | PHASE1 |
| NCT01605162 | TERMINATED | Wild Type BRAF Stage IV Melanoma; Unresectable Stage III Melanoma |
Eisai Inc. |
2012-05 | PHASE2 |
| NCT00583492 | COMPLETED | Prostate Cancer |
Henry Ford Health System |
2007-12 | PHASE2 |
| NCT01051596 | COMPLETED | Colorectal Cancer |
Georgetown University |
2009-09 | PHASE2 |
| NCT01339819 | COMPLETED | Atrial Fibrillation |
Deutsches Herzzentrum Muenchen |
2011-04 | PHASE4 |
| NCT00946335 | COMPLETED | Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Ependymoblastoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Low-grade Cerebellar Astrocytoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Brain Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Spinal Cord Neoplasm; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma |
National Cancer Institute (NCI) |
2009-07 | PHASE1 |
| NCT01045304 | COMPLETED | Breast Cancer, Metastatic |
Sanofi |
2010-02 | PHASE2 |
| NCT01127178 | TERMINATED | Solid Tumors |
Eisai Inc. |
2010-03-29 | PHASE1 |
| NCT00516373 | COMPLETED | Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein |
AstraZeneca |
2005-07-11 | PHASE1 |
| NCT00387608 | COMPLETED | Leukemia; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific |
National Institutes of Health Clinical Center (CC) |
2006-06 | PHASE1 |
| NCT00415454 | TERMINATED | Pancreatic Cancer |
Henry Ford Health System |
2006-11 | PHASE1 |
| NCT00994071 | COMPLETED | Medulloblastoma; Pontine Glioma; Ependymoma; Astrocytoma; PNET |
National Cancer Institute (NCI) |
2009-09-22 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-11)
Check the
ADP
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.